

SUPPLEMENTAL REFERENCES

1. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *J Hepatol* 2020;73:202-209.
2. Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, et al. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. *Gut* 2023;72:141-152.
3. Myers S, Neyroud-Caspar I, Spahr L, Gkouvatso K, Fournier E, Giostra E, et al. NAFLD and MAFLD as emerging causes of HCC: A populational study. *JHEP Rep* 2021;3:100231.
4. Lin YP, Wang PM, Chuang CH, Yong CC, Liu YW, Huang PY, et al. Metabolic risks are increasing in non-b non-C early-stage hepatocellular carcinoma: A 10-year follow-up study. *Front Oncol* 2022;12:816472.
5. Kim MN, Han K, Yoo J, Hwang SG, Ahn SH. Metabolic dysfunction-associated fatty liver disease subgroups and risk of hepatocellular carcinoma and mortality in patients with chronic viral hepatitis. *J Hepatol* 2022;77:S100.
6. Shaikh A, Lymberopoulos P, Benhammou JN, Rich NE, Patel A, Bhatnagar A, et al. Clinical impact of metabolic-associated fatty liver disease on liver transplantation for hepatocellular carcinoma. *Hepatology*. Hoboken: Wiley, 2022.
7. Xiong KG, Lin TS, Kong JF, Lin QB, Chen LF, Ke KY. Impact of MAFLD on the complications after hepatectomy in patients with HBV-related hepatocellular carcinoma. *Medicine (Baltimore)* 2023;102:e33062.
8. Xiong KG, Ke KY, Chen LF, Kong JF, Lin TS, Lin QB, et al. The impact of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with hepatocellular carcinoma after radical resection. *Hepatobiliary Pancreat Dis Int* 2023;22:366-372.
9. Shimose S, Hiraoka A, Casadei-Gardini A, Tsutsumi T, Nakano D, Iwamoto H, et al. The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma. *Hepatol Res* 2023;53:104-115.
10. Nakagawa M, Inoue M, Ogasawara S, Maruta S, Okubo T, Itokawa N, et al. Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice. *Cancer* 2023;129:590-599.
11. Yun B, Ahn SH, Oh J, Yoon JH, Kim BK. Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study. *Hepatol Res* 2022;52:975-984.
12. Xue J, Wang QX, Xiao HM, Shi MJ, Xie YB, Li S, et al. Impact of metabolic dysfunction associated fatty liver disease on the prognosis of patients with hepatitis B virus-related hepatocellular carcinoma based on propensity score matching analysis. *Cancer Manag Res* 2022;14:2193-2202.
13. Amano K, Kawaguchi T, Ide T, Tsutsumi T, Sano T, Nakano D, et al. Effect of maflD on liver carcinogenesis in hbeag negative patients with undetectable hbvDNA under nucleos(t)ide analogs therapy. *Hepatology* 2022;76(Suppl 1):S243.
14. Clark-Dickson M, Chu E, Kim H, Plasto T, Jones B, Nguyen V. Outcomes after hepatocellular carcinoma treatment in a single tertiary center in Australia. *J Gastroenterol Hepatol* 2022;37(Suppl 1):50.
15. Iyer KG, Flores JE, Macisaac M, Gilmore R, Loebenstein M, Tambakis G, et al. Surveillance uptake remains a key challenge to timely detection of early-stage hepatocellular carcinoma in Australia: A single-site, retrospective cohort study of hepatocellular carcinoma diagnosis in Melbourne. *J Gastroenterol Hepatol* 2022;37(Suppl 1):73.
16. Lin YP, Lin SH, Wang CC, Lin CC, Chen DW, Chuang CH, et al. Impact of MAFLD on HBV-related stage 0/A hepatocellular carcinoma after curative resection. *J Pers Med* 2021;11:684.
17. Liu L, Xie S, Teng YX, Deng ZJ, Chen K, Liu HT, et al. Outcomes of liver resection for metabolic dysfunction-associated fatty liver disease or chronic hepatitis B-related HCC. *Front Oncol* 2022;11:783339.
18. Liu Z, Suo C, Shi O, Lin C, Zhao R, Yuan H, et al. The health impact of MAFLD, a novel disease cluster of NAFLD, is amplified by the integrated effect of fatty liver disease-related genetic variants. *Clin Gastroenterol Hepatol* 2022;20:e855-e875.
19. Rodrigues B, Bloom S, Sawhney R, Bishara M, Ramachandran V, Huang H, et al. Metabolic-associated fatty liver disease and hepatocellular carcinoma risk: A prospective analysis of clinic trends and outcomes (the Pro FAITH study). *J Gastroenterol Hepatol* 2021;36(Suppl 3):50-51.
20. van Kleef LA, Choi HSJ, Brouwer WP, Hansen BE, Patel K, de Man RA, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. *JHEP Rep* 2021;3:100350.
21. Vanlerberghe BTK, van Malenstein H, Sainz-Bariga M, Jochmans I, Cassiman D, Monbaliu D, et al. Utility and prognostic value of diagnosing MAFLD in patients undergoing liver trans-

- plantation for alcohol-related liver disease. *Clin Transplant* 2023;37:e14965.
22. Xie X, Zheng M, Guo W, Zhou Y, Xiang Z, Li Y, et al. Correlation analysis of metabolic characteristics and the risk of metabolic-associated fatty liver disease - related hepatocellular carcinoma. *Sci Rep* 2022;12:13969.
23. Gonzalez-Chagolla A, Olivas-Martinez A, Ruiz-Manriquez J, Servín-Rojas M, Kauffman-Ortega E, Chávez-García LC, et al. Cirrhosis etiology trends in developing countries: Transition from infectious to metabolic conditions. Report from a multicentric cohort in central Mexico. *Lancet Reg Health Am* 2021;7:100151.